Becton Dickinson (BDX) announced that the FDA has granted 510 clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy system designed to provide clinicians with flexibility across breast imaging modalities in the diagnosis of breast disease.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Becton Dickinson to invest $110M to expand prefillable syringe production
- Becton Dickinson price target raised to $215 from $210 at Stifel
- Becton Dickinson price target raised to $207 from $190 at BofA
- Becton Dickinson, University of Pennsylvania partner on human immune profiling
- Becton Dickinson price target raised to $210 from $202 at RBC Capital